Literature DB >> 931795

Metabolic fate of cephacetrile after parenteral administration in rats and rabbits.

Y Nakai, Y Kanai, T Fugono, S Tanayama.   

Abstract

1. The metabolic fate of 14C-cephacetrile was studied in rats and rabbits. The plasma level of intravenously injected cephacetrile decreased with half-lives of 17 and 22 minutes in rats and rabbits respectively, this decline being associated with a rapid appearance of the active metabolite, desacetylcephacetrile. Intramuscularly injected cephacetrile was rapidly absorbed by rats with a maximum plasma level at 20 minutes and a half-life of 16 minutes. Cephacetrile and desacetylcephacetrile did not enter erythrocytes. Cephacetrile was weakly bound to the plasma protein in the rat, rabbit and man. 2. Both in rats and rabbits, almost all of the injected radioactivity was excreted in the urine within 72 hours as the intact antibiotic and desacetylcephacetrile, only small amounts appearing in feces via bile. Neither the gamma-lactone of desacetyl-7-cyanacetamidocephalosporanic acid nor the violet-reddish pigment (CGP-695) produced from cephacetrile were detectable in the plasma or urine of the animals. 3. In rats given the labeled antibiotic intravenously, the radioactivity was widely distributed with concentrations being high in the kidney, plasma and liver, and lowest in the brain. The radioactivity crossed the rat placenta and appeared in the fetus. Radioactivity in these tissues disappeared as the plasma level declined. 4. During daily intramuscular injection of 14C-cephacetrile to rat, no significant changes were observed in the peak level of the plasma radioactivity or in the half-lives. In addition, dosing of the labeled antibiotic for 7 days caused no increase in tissue levels of radioactivity.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 931795     DOI: 10.7164/antibiotics.29.81

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  7 in total

1.  Metabolic fate of [14C]SM-1652, a new antipseudomonal cephalosporin, after parenteral administration to rats.

Authors:  H Imasaki; Y Enjoji; H Matsui; R Kawai; S Kawamura; T Okuda
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

2.  Pharmacokinetics of the cephalosporin SM-1652 in mice, rats, rabbits, dogs, and rhesus monkeys.

Authors:  H Matsui; K Yano; T Okuda
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

3.  Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals.

Authors:  M Komiya; Y Kikuchi; A Tachibana; K Yano
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

4.  The current state of cephalosporin antibiotics: microbiological aspects.

Authors:  H Knothe; G A Dette
Journal:  Infection       Date:  1983       Impact factor: 3.553

5.  Metabolic fate of SCE-129, a new antipseudomonal cephalosporin, after parenteral administration in rats and dogs.

Authors:  S Tanayama; K Yoshida; Y Kanai
Journal:  Antimicrob Agents Chemother       Date:  1978-07       Impact factor: 5.191

6.  Metabolic fate of SCE-1365, a new broad-spectrum cephalosporin, after parenteral administration to rats and dogs.

Authors:  S Tanayama; K Yoshida; K Adachi; T Kondo
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

7.  Disposition of carumonam (AMA-1080/Ro 17-2301), a new N-sulfonated monocyclic beta-lactam, in rats and dogs.

Authors:  K Yoshida; M Mitani; I Naeshiro; H Torii; S Tanayama
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.